Clinical Trial: Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors, A Feasibility Study

Brief Summary: To determine if FDOPA-PET/MRI imaging can predict response to treatment of bevacizumab.

Detailed Summary: Evaluate the feasibility of using FDOPA-PET/MRI pediatric patients with CNS tumors. Positive results in this small study would provide the data needed to expand the study to validate the use in a larger population of pediatric patients. Validating the use of FDOPA-PET imaging as an early predictor for response to anti-angiogenic therapy could greatly impact the standard of care for treating and evaluating pediatric brain tumors and provide a useful biomarker for assessing experimental therapeutics.
Sponsor: Washington University School of Medicine

Current Primary Outcome: FDOPA-PET/MRI imaging [ Time Frame: 1 year ]

The imaging is evaluated: (a) the uptake of PET tracer FDOPA measured by average and maximal standardized uptake values (SUVs) as well as tumor to normal brain ratios; and (b) tumor volumes defined by MRI signal abnormality.


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Washington University School of Medicine

Dates:
Date Received: November 25, 2013
Date Started: April 2013
Date Completion:
Last Updated: October 19, 2016
Last Verified: October 2016